https://www.live-feeds.com/feed/chinese-biopharma-stocks-jump-as-u-s-weighs-keeping-door-open-to-drug-dealsContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/chinese-biopharma-stocks-jump-as-u-s-weighs-keeping-door-open-to-drug-dealshttps://www.live-feeds.com/feed/chinese-biopharma-stocks-jump-as-u-s-weighs-keeping-door-open-to-drug-deals#u80553Tue, 22 Sep 2026 21:01:08 +0000Chinese biopharma stocks surged as the United States considers keeping the door open for pharmaceutical licensing deals and American investments involving China. Analysts note a potential high tide of biotech deals as fears of strict American curbs begin to fade. Legislative attention previously focused on massive growth in U.S.-China biotech deals, which jumped from five billion dollars to one hundred thirty-six billion dollars, prompting Congress to seek guardrails such as the BIOSECURE Act. Industry general counsels and retail investors are closely tracking these regulatory developments as